Pharmacogenomics in early-phase clinical development.

Loading...
Thumbnail Image

Date

2013-07

Journal Title

Journal ISSN

Volume Title

Repository Usage Stats

167
views
338
downloads

Citation Stats

Abstract

Pharmacogenomics (PGx) offers the promise of utilizing genetic fingerprints to predict individual responses to drugs in terms of safety, efficacy and pharmacokinetics. Early-phase clinical trial PGx applications can identify human genome variations that are meaningful to study design, selection of participants, allocation of resources and clinical research ethics. Results can inform later-phase study design and pipeline developmental decisions. Nevertheless, our review of the clinicaltrials.gov database demonstrates that PGx is rarely used by drug developers. Of the total 323 trials that included PGx as an outcome, 80% have been conducted by academic institutions after initial regulatory approval. Barriers for the application of PGx are discussed. We propose a framework for the role of PGx in early-phase drug development and recommend PGx be universally considered in study design, result interpretation and hypothesis generation for later-phase studies, but PGx results from underpowered studies should not be used by themselves to terminate drug-development programs.

Department

Description

Provenance

Citation

Published Version (Please cite this version)

10.2217/pgs.13.81

Publication Info

Burt, Tal, and Savita Dhillon (2013). Pharmacogenomics in early-phase clinical development. Pharmacogenomics, 14(9). pp. 1085–1097. 10.2217/pgs.13.81 Retrieved from https://hdl.handle.net/10161/9359.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.


Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.